AGTR1 and cancer: Numerous retrospective clinical studies acknowledge significant improvement in overall survival, progression-free survival, and disease-free survival in patients with cancer using RASi as antihypertensive medication.30 There is a clear upregulation of the RAS component, AT1R within the adenoma–colorectal–liver metastasis axis.31 32 Experimental and clinical studies over the last decade indicate that RASi impairs tumor progression through modulation of the tumor vasculature33 34 and tumor desmoplasia35; thus far, its role in tumor immunoregulation is not yet clear.